Why the study?
The study aimed to develop atorvastatin-loaded emulgel and nano-emulgel dosage forms and investigate their efficiency on surgical wound healing and post-operative pain reduction.
Does topical atorvastatin-loaded emulgel and nano-emulgel 1% improve wound healing and reduce pain in adults undergoing laparotomy?
Does topical atorvastatin-loaded emulgel and nano-emulgel 1% improve wound healing and reduce pain in adults undergoing laparotomy?
Topical atorvastatin-loaded emulgel and nano-emulgel 1% significantly accelerate wound healing and alleviate pain in post-laparotomy surgical wounds.
Answers are grounded in this paper and cite their sources.
Supports topical atorvastatin emulgel for faster post-laparotomy healing and less pain; extends statin repurposing to surgical wounds.
This study aimed to develop atorvastatin-loaded emulgel and nano-emulgel dosage forms and investigate their efficiency on surgical wound healing and reducing post-operative pain. This double-blind randomized clinical trial was conducted in a surgical ward of a tertiary care hospital affiliated with university of medical sciences. The eligible patients were adults aged 18 years or older who were undergoing laparotomy. The participants were randomized in a 1:1:1 ratio to one of three following groups of atorvastatin-loaded emulgel 1% (n = 20), atorvastatin-loaded nano-emulgel 1% (n = 20), and placebo emulgel (n = 20) twice a day for 14 days. The primary outcome was the Redness, Edema, Ecchymosis, Discharge, and Approximation (REEDA) scores to determine the rate of wound healing. The Visual Analogue Scale (VAS) and quality of life were the secondary outcomes of this study. A total of 241 patients assessed for eligibility; of them, 60 patients completed the study and considered for final evaluation. A significant decrease in REEDA score was observed on Days 7 (63%) and 14 (93%) of treatment with atorvastatin nano-emulgel (p-value < 0.001). A significant decrease of 57% and 89% in REEDA score was reported at Days 7 and 14, respectively, in atorvastatin the emulgel group (p-value < 0.001). Reduction in pain VAS in the atorvastatin nano-emulgel was also recorded at Days 7 and 14 of the intervention. The results of the present study suggested that both topical atorvastatin-loaded emulgel and nano-emulgel 1% were effective in acceleration of wound healing and alleviation of pain of laparotomy surgical wounds, without causing intolerable side effects.
No takes yet. Share an insight, caveat, or question.
Saghafi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: